Peter Greenleaf - 02 Mar 2023 Form 4/A Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: AUPH
Reported as of: 02 Mar 2023
Net transaction value: -$290,153
SEC form: 4/A
Accepted by SEC: 22 Feb 2024, 16:15:26 UTC
Original report date: 06 Mar 2023
Prior SEC filing: 26 May 2022
Next SEC filing: 22 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Peter S. Greenleaf

Key filing fact

Peter Greenleaf filed Form 4/A for Aurinia Pharmaceuticals Inc. (AUPH) on 22 Feb 2024.

Key facts

This page summarizes Peter Greenleaf's Form 4/A filing for Aurinia Pharmaceuticals Inc. (AUPH).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 22 Feb 2024, 16:15.

Change

Previous filing in this sequence was filed on 26 May 2022.
Current net transaction value: -$290,153.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AUPH transaction

Common Stock

Sale

Transaction value: $290,153
Shares: -33,047
Change %: -3.3%
Price: $8.78
Shares after: 982,671
Date: 02 Mar 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs.

SEC remarks

This amendment is being filed to amend the Form 4 filed on March 6, 2023 with the SEC in order to correct the amount sold, price per share and total securities owned after the transaction.